We investigated whether increased concentrations of inspired oxygen (FiO 2 ) affects exercise tolerance in patients with heart failure and normal ejection fraction (HeFNEF).
Introduction
Epidemiological studies suggest that heart failure with normal ejection fraction (HeFNEF) accounts for almost 50% of patients with heart failure (HF), and its prevalence is increasing. 1, 2, 3 Compared to patients with heart failure and reduced ejection fraction (HeFREF), those with HeFNEF are usually older and have more comorbidities, 4 which plays a significant role in the development and/or worsening of HF symptoms and substantially contributes to the adverse prognosis of patients with HeFNEF. HeFNEF is a heterogeneous clinical syndrome which can be difficult to diagnose and treat. 4 Clinical trials have failed to demonstrate that any pharmacological treatment improves outcomes for patients with HeFNEF. 5, 6, 7, 8, 9, 10 However, another important aim of treatment is to alleviate symptoms and to improve wellbeing. 11 The clinical hallmark of HeFNEF is exertional breathlessness, at least partially due to an abnormal increase in left atrial pressure during exercise. 4 Reduction in delivery of oxygen to the periphery and myocardium might contribute to, and aggravate, breathlessness and fatigue. 4 Small trials suggest that increasing inspired oxygen concentration during exercise might prolong exercise time and improve symptoms in patients with HeFREF or pulmonary hypertension, 12, 13, 14 but the effect on patients with HeFNEF is unknown.
We aimed to assess the effects of increasing inspired oxygen fraction (FiO 2 ) on exercise capacity in patients with HeFNEF.
Methods
This was a single centre, randomised , single-blinded, cross-over trial in patients with HeFNEF. The research conforms to the Helsinki declaration. Ethics approval was granted by 
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Shah et al STOP-EF 01/05/18 5 rhythm were continuously monitored. The three exercise tests were conducted at approximately weekly intervals.
The primary endpoint was exercise time (ET; seconds). Secondary end points included: peak workload (watts), modified Borg score, peak heart rate (beats per minute), and peak arterial oxygen saturation (O 2 sat; percentage).
Statistical analysis
Categorical data are presented as number and percentages; normally distributed continuous data as mean ± standard deviation (SD) and non-normally distributed continuous variables as median and interquartile range.
Between-group means of the primary and secondary endpoints were compared using analysis of variance (ANOVA). The method uses 'least squares' to fit linear models. We used oneway ANOVA with repeated measures on dose-group. An underlying assumption of the F test is independence of observations. In a repeated measures design, this assumption is almost certainly violated (observations from the same subject are likely to be correlated). To overcome this, we used a correction factor (a number have been proposed in the literature) to the degrees-of-freedom for the F test. We chose one developed by Box which is conservative in a statistical sense (if significant by Box it will be significant by the rest). 16 Other assumptions of ANOVA were met. Paired t-tests were then used to compare the primary and secondary endpoints between exercise tests.
Sub-group analysis of the primary and secondary endpoints were pre-specified and used to explore the relation between age, haemoglobin, creatinine, NTproBNP, body mass index (BMI), sex, the use of a walking aid and heart rhythm (atrial fibrillation vs sinus rhythm) and
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Shah et al STOP-EF 01/05/18 6 the end points. The current European Society of Cardiology guidelines on heart failure set an LVEF cut-off at 50% for diagnosing HeFNEF, so we re-analysed the results for patients above and below this LVEF cut-off. 11 Primary and secondary endpoints are shown in boxplots. All analyses were performed on SPSS (V 23.0) and Stata statistical computer packages. A statistical significance was assumed at P<0.05 (two tailed).
There were no missing values for exercise time so an analysis of missing data by multiple imputations was unnecessary. 17
Results
Of the 50 patients enrolled, 46 patients completed the three visits, and 4 withdrew.
( Supplementary Figure 1) . Increasing FiO 2 had no effect peak workload (P=0.50) and modified Borg score (P=0.17).
( Supplementary Table 1 ; Figure 1 ) There was no effect of increasing FiO 2 on heart rate during exercise (P=0.65), although arterial oxygen saturation throughout exercise was higher with increasing FiO 2 (P=0.03). ( Supplementary Table 1 )
Patients with LVEF > 50% had a lower exercise time and peak workload than those with LVEF between 45-49%, but had a slightly greater increase in exercise time with the increase Table 3 )
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Discussion
We have found that in patients with HeFNEF, increasing oxygen concentration during exercise lead to a small increase in exercise time but had no effect on peak work load.
There are no previous trials of supplementary oxygen during exercise in patients with
HeFNEF. Trials of oxygen supplementation during exercise in patients with heart failure with reduced ejection fraction (HeFREF) have yielded mixed results. Moore and colleagues reported a dose dependent increase in exercise time from 548 ±275 seconds on room air to 632 ±288 seconds with FiO 2 of 50% in 12 patients with HeFREF during resistance cycling on a stationary bike to maximum capacity (workload was increased by 15 W at 2-min intervals). 12 In contrast, Russell and colleagues found no effect of increasing FiO 2 to 60% on exercise time compared to 21% FiO 2 during symptom limiting resistance cycling on a stationary bike (2-minute resting period followed by increasing workloads of 25 W every 3 minutes) in 16 patients with LVEF <35%. 18 Restrick found no effect of oxygen delivered at 4 l/min on 6 minute walk test distance in 12 patients with stable chronic heart failure. 19 We studied 31 patients with HeFREF (mean LVEF 31%) and found that exercise time, maximal workload and maximal metabolic equivalent all increased significantly with increasing FiO 2 from 21%, to 28% and 40% FiO 2 . 13 In a study of 22 patients with pulmonary hypertension (pulmonary arterial or chronic thrombo-embolic pulmonary hypertension), increasing FiO 2 to to be older than those with HeFREF, are more likely to be overweight or obese and have chronic lung problems (and other comorbidities including anaemia). 20, 21 Sarcopenia and loss of muscle bulk are common in older people and particularly in patients with HeFNEF. 22 Patients with HeFNEF are thus, perhaps, more likely to have conditions other than their heart failure that limits exercise, and hence oxygen is less likely to help their exercise performance.
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In the present study, overall we found no relation between cardiac rhythm or plasma NTproBNP and exercise time. We found, perhaps paradoxically, that patients with LVEF between 45-49% had a longer ET than those with higher LVEF (>50%), despite having a significantly greater plasma NTproBNP and lower haemoglobin level. Patients with LVEF between 45-49% may represent patients who truly have lower exercise capacity due to heart failure rather than those with LVEF >50% whose exercise performance might not be entirely related to the heart. 23 The mechanisms causing exercise intolerance in patients with heart failure are complex. 24 In most stable ambulatory patients with HeFREF, haemodynamics at rest are not substantially impaired. 25 Major determinants of exercise capacity appear to lie in the periphery, with abnormal skeletal muscle performance being chiefly implicated. The situation may be different in patients with HeFNEF: again, haemodynamics at rest may be normal, but during exercise, there is a disproportionate increase in left atrial pressure, 26 which contributes to
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Trials in patients with
HeFNEF which have exercise capacity as a primary endpoint may be likely to fail due to the heterogeneity of the condition.
Limitations
We only enrolled patients able to exercise. We also only included patients treated with a diuretic; this might have led to a population of patients with HeFNEF with a more severe disease profile. 28 Monitoring central haemodynamics during exercise testing might have added to the understanding of the causes of exercise intolerance in patients with HeFNEF.
We included some patients who had an LVEF 45% -49% on echocardiography. According to the current ESC HF guidelines, these patients would fall into the newly introduced category of "heart failure with mid-range ejection fraction" (HFmrEF). 11 Such patients might represent a separate phenotype from patients with HeFNEF.
Conclusions
Increasing FiO 2 during exertion leads to a small increase in exercise time in patients with
HeFNEF which is unlikely to be clinically significant. 
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